Analysis of 1764 patients from 2 RCTs and 13 observational studies found no significant difference in developmental delay or cerebral palsy risk between anti‐VEGF and laser therapy (RR 1.05; 95% CI 0.96–1.15; Figure 6). The gene discussed is VEGFA; the disease is cerebral palsy.